foxo4-dri senolytic or senomorphic

foxo4-dri senolytic or senomorphic UK | Peptide Research Molecular modelling of the FOXO4-TP53

Name: foxo4-dri senolytic or senomorphic UK | Peptide Research Molecular modelling of the FOXO4-TP53
Brand: lagence-mr.com
SKU: 71300734810
Price: 23.92 USD
Availability: InStock
Rating: 4.6336 (12 reviews)

Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity. FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC

SKU: 71300734810 · From lagence-mr.com

4.6

USD23.92 USD51.92

Pay in 4 interest-free payments of $5.98 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 5 - Aug 10

Description

Gaussian distribution of data was confirmed before testing using the DAgostinoPearson normality test

S., Amaro, A

Furthermore, PDA is a potent stimulator of F-actin production in fibroblasts

BPC-157 is a pentadecapeptide and a potential drug under investigation for its healing properties, cytoprotective effects, and regenerative potential across various tissues and organs